"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 5 | 6 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 7 | 2 | 9 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 4 | 5 | 9 |
| 2012 | 2 | 6 | 8 |
| 2013 | 2 | 3 | 5 |
| 2014 | 4 | 2 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 8 | 10 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 5 | 7 |
| 2019 | 1 | 3 | 4 |
| 2020 | 5 | 6 | 11 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 3 | 4 | 7 |
| 2025 | 2 | 4 | 6 |
| 2026 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Clin Lab Med. 2026 Sep; 46(3):607-622.
-
Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study. Cancer Imaging. 2026 Aug 25; 26(1).
-
18F-FDOPA PET/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1. Front Endocrinol (Lausanne). 2026; 17:1849746.
-
Radiation Segmentectomy versus Combined Chemoembolization plus Microwave Ablation: Histopathologic Tumor Necrosis in Hepatocellular Carcinoma Measuring up to 5 cm. J Vasc Interv Radiol. 2026 Oct; 37(10):108926.
-
Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging. Eur J Med Chem. 2026 Jul 05; 311:118803.
-
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141). Leuk Lymphoma. 2025 Dec; 66(14):2765-2773.
-
A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT. Bioorg Med Chem Lett. 2025 Dec 15; 129:130394.
-
Molecular PET imaging: Unlocking the secrets of cancer metabolism. Biochem Pharmacol. 2025 12; 242(Pt 3):117202.
-
Diagnoses and outcomes of patients referred for FDG PET/CT for suspected cardiac sarcoidosis. Int J Cardiol. 2025 11 15; 439:133643.
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.